Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers

Oral Diseases

Volumn 17, Issue 8, 2011, Pages 794-800

  Supic, G ^a   Kozomara, R ^a   Jovic, N ^a   Zeljic, K ^a   Magic, Z ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

DNA methylation; Nodal and tumor stage; Oral squamous cell carcinoma; RUNX3; Tongue carcinoma; WIF1

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL FEATURE; DNA METHYLATION; FEMALE; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TONGUE CANCER; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SMOKING; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054082401     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01838.x     Document Type: Article

References (47)

1. Ahlquist T, Lind G, Costa V et al (2008). Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 7: 94-99.
2. Ai L, Tao Q, Zhong S et al (2006). Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 27: 1341-1348.
3. Cao J, Zhou J, Gao Y et al (2009). Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin Cancer Res 15: 5178-5183.
4. Chan S, Cui Y, van Hasselt A et al (2007). The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 87: 644-650.
5. Chen W, Gao N, Shen Y, Cen J (2010). Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 25: 823-831.
6. Clément G, Guilleret I, He B et al (2008). Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 99: 46-53.
7. Gao F, Huang C, Lin M et al (2009). Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol 135: 739-747.
8. Herman J, Baylin S (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
9. Herman J, Graff J, Myohanen S et al (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
10. Ito K, Liu Q, Salto-Tellez M et al (2005). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750.
11. Ito K, Lim A, Salto-Tellez M et al (2008). RUNX3 attenuates b-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237.
12. Iwai S, Katagiri W, Kong C et al (2005). Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol 13: 773-782.
13. Kim W, Kim E, Jeong P et al (2005). RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65: 9347-9354.
14. Kudo Y, Tsunematsu T, Takata T (2011). Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem 112: 387-393.
15. Lau Q, Raja E, Salto-Tellez M et al (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520.
16. Lee B, Lee E, Jung E et al (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15: 6185-6191.
17. Licchesi J, Westra W, Hooker C et al (2008). Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29: 895-904.
18. Lin YC, You L, Xu Z et al (2006). Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun 341: 635-640.
19. Lo Muzio L (2001). A possible role for the WNT-1 pathway in oral carcinogenesis. Crit Rev Oral Biol Med 12: 152-165.
20. Long C, Yin B, Lu Q et al (2007). Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest 25: 685-690.
21. Magic Z, Supic G, Brankovic-Magic M (2009). Towards targeted epigenetic therapy of cancer. J BUON 14(Suppl 1): S79-S88.
22. Mazieres J, He B, You L et al (2004). Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64: 4717-4720.
23. Palmisano W, Divine K, Saccomanno G et al (2000). Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958.
24. Pannone G, Bufo P, Santoro A et al (2010). WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep 24: 1035-1041.
25. Park S, Kwon H, Lee H et al (2011). Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 458: 73-84.
26. Reguart N, He B, Xu Z et al (2004). Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun 323: 229-234.
27. Rhee C, Sen M, Lu D et al (2002). Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 21: 6598-6605.
28. Romana PG (2010) Cell alterations and molecular mechanisms in oral carcinogenesis. Int J Oral Maxillofac Surg doi:.
29. Sailasree R, Abhilash A, Sathyan K, Nalinakumari K, Thomas S, Kannan S (2008). Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol Biomarkers Prev 17: 414-420.
30. Salto-Tellez M, Peh BK, Ito K et al (2006). RUNX3 protein is overexpressed in human basal cell carcinomas. Oncogene 25: 7646-7649.
31. Schulmann K, Sterian A, Berki A et al (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24: 4138-4148.
32. Scully C, Bagan J (2009). Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis 15: 388-399.
33. Shaw R (2006). The epigenetics of oral cancer. Int J Oral Maxillofac Surg 35: 101-108.
34. Shaw R, Hall G, Woolgar J et al (2007). Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 45: 617-622.
35. Su P, Huang W, Wu H, Wu C, Liu T, Kao S (2010). p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner. Oral Oncol 46: 734-739.
36. Subramaniam M, Chan J, Yeoh K et al (2009). Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
37. Supic G, Kozomara R, Brankovic-Magic M, Jovic N, Magic Z (2009). Gene hypermethylation in tumor tissue of advanced oral squamous cell carcinoma patients. Oral Oncol 45: 1051-1057.
38. Supic G, Jovic N, Kozomara R, Zeljic K, Magic Z (2011). Interaction between the MTHFR C677T polymorphism and alcohol - impact on oral cancer risk and multiple DNA methylation of tumor-related genes. J Dent Res 90: 65-70.
39. Tan SH, Ida H, Goh BC, Hsieh W, Loh M, Ito Y (2006). Analyses of promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma. Anticancer Res 26: 4287-4292.
40. Tanji Y, Osaki M, Nagahama Y, Kodani I, Ryoke K, Ito H (2007). Runt-related transcription factor 3 expression in human oral squamous cell carcinomas; implication for tumor progression and prognosis. Oral Oncol 43: 88-94.
41. Torquati A, O'rear L, Longobardi L, Spagnoli A, Richards W, Daniel B (2004). RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 136: 310-316.
42. Tsunematsu T, Kudo Y, Iizuka S et al (2009). RUNX3 has an oncogenic role in head and neck cancer. PLoS ONE 4: 1-12.
43. Urakami S, Shiina H, Enokida H et al (2006). Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 12: 383-391.
44. Williams HK (2000). Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 53: 165-172.
45. Wissmann C, Wild PJ, Kaiser S et al (2003). WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201: 204-212.
46. Yanagawa N, Tamura G, Oizumi H et al (2007). Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58: 131.
47. Yang F, Zeng Q, Yu G, Li S, Wang C (2006). Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 18: 679-687.